重大事件
外國發行人報告
6-K
2026-07-09
Alterity Therapeutics 獲澳洲政府近400萬澳元研發退稅 支持ATH434第三期試驗
AI 繁中摘要
6-K 申報文件摘要：Alterity Therapeutics 獲澳洲政府研發稅務優惠退款
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) 於2026年7月9日公佈，已收到澳洲政府2025財政年度（截至2025年6月底）的研發稅務退款，總額為澳元3,982,992元（約美元2,640,000元），當中包括澳元43,117元利息。此退款來自澳洲政府的R&D稅務優惠計劃，合資格企業可獲最高43.5%的可退還稅務抵免。該筆資金將為公司持續開發臨床項目提供重要支持。
Alterity 是一家專注神經退化性疾病（neurodegenerative diseases）的臨床階段生物科技公司，正準備為其候選藥物 ATH434 啟動第三期關鍵性試驗（Phase 3 pivotal trial），針對多系統萎縮症（MSA）——一種罕見且快速進展的疾病。ATH434 在之前隨機、雙盲、安慰劑對照的第二期臨床試驗中，已展現出臨床意義的療效；另在開放標籤第二期試驗中，針對晚期 MSA 患者亦報告正面數據。
管理層未有在文件中直接發表展望，但指出退款將支持臨床項目推進。對投資者而言，此項非攤薄性的資金注入有助延長公司現金跑道，並為第三期試驗的啟動提供財務緩衝。鑑於 MSA 目前尚無獲批的疾病修飾治療，ATH434 若成功研發，將具顯著的市場潛力。然而，投資者仍應留意臨床試驗結果、監管審批及融資等風險因素。
展開英文正文
EX-99.1 2 ex_986208.htm EXHIBIT 99.1 ex_986208.htm Exhibit 99.1 Alterity Therapeutics Receives A$3.98m R&D Tax Incentive MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 9 July 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received its research and development (R&D) tax refund for the 2025 financial year, totaling A$3,982,992, including A$43,117 interest. The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%. The refund received will provide important funding for continued development of Alterity’s clinical programs. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com. Authorization & Additional Information This announcement was authorized by the Board of Directors of Alterity Therapeutics Limited. Contacts: Investors Elyse Shapiro [email protected] Remy Bernarda Investor Relations Advisory Solutions [email protected] +1 (415) 203-6386 Media Melissa Tempra NWR Communications [email protected] Casey McDonald Tiberend Strategic Advisors, Inc. [email protected] +1 (646) 577-8520 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.